|
Drug
|
Sensitivitya
|
Specificityb
|
Drug concentration (ng/mg)
|
|---|
|
True positives
|
False positives
|
|---|
|
No. detected/no. taking drugs
|
% (95% CI)
|
No. not detected/no. not taking drugs
|
% (95% CI)
|
Median (IQR)
|
Median (IQR)
|
|---|
|
Isoniazid
|
31/33
|
93.9 (79.8–99.3)
|
12/20
|
60 (36.1–80.9)
|
0.99 (0.32–2.21)
|
0.33 (0.25–0.46)
|
|
Pyrazinamide
|
54/54
|
100 (93.3–100)
|
0/2
|
0 (0–84.2)
|
9.84 (4.52–18.54)
|
0.26 (0.22–0.38)
|
|
Ethambutol
|
45/45
|
100 (92.1–100)
|
0/10
|
0 (0–30.8)
|
0.92 (0.43–1.53)
|
0.05 (0.02–0.35)
|
|
Levofloxacin
|
30/30
|
100 (88.4–100)
|
2/26
|
7.7 (0.9–25.1)
|
26.46 (11.53–48.08)
|
0.63 (0.32–1.06)
|
|
Moxifloxacin
|
41/41
|
100 (91.4–100)
|
0/13
|
0 (0–26.5)
|
13.81 (6.23–18.32)
|
2.04 (0.46–4.91)
|
|
Linezolid
|
22/23
|
95.6 (78.1–99.9)
|
26/32
|
81.3 (64.6–92.8)
|
9.12 (4.20–17.66)
|
0.16 (0.14–0.43)
|
|
Clofazimine
|
34/34
|
100 (89.7–100)
|
2/22
|
9.1 (1.1–29.2)
|
2.98 (1.39–4.59)
|
0.20 (0.05–0.67)
|
|
Bedaquiline
|
27/27
|
100 (87.2–100)
|
7/28
|
25 (10.7–44.9)
|
0.90 (0.71–1.46)
|
0.21 (0.10–0.35)
|
|
Pretomanid
|
1/1
|
100 (2.5–100)
|
55/56
|
98.2 (90.4–100)
|
-c
|
–
|
|
Ethionamide
|
20/34
|
58.5 (40.7–99.9)
|
20/20
|
100 (83.2–100)
|
–
|
–
|
- a For sensitivity, the reference standard was considered ‘positive’ if the drug was taken for at least 14 days during the hair growth window
- b For specificity, the reference standard was considered ‘negative’ if the drug is not taken for any days in the previous 124 days prior to and including the day of hair collection. For BDQ and CFZ, the reference standard was ‘negative’ if there was no known history of past use of the drug at any time
- c Not enough data points for comparison
